Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells --
-- Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab and potential milestone payments up to $1.188 billion --
-- Xencor management to host conference call today at 8:00 a.m. ET (5:00 a.m. PT) --
Conference Call
Xencor management will host a conference call today at 8:00 a.m. ET (5:00 a.m. PT) to discuss the agreement.
The live call may be accessed by dialing (877) 359-9508 for domestic callers or +1 (224) 357-2393 for international callers and referencing conference ID number 8580556. A live webcast of the conference call will be available online from the Investors section of Xencor's website at www.xencor.com. The call will be archived on Xencor's website for 30 days.
https://finance.yahoo.com/news/xencor-enters-global-collaboration-license-110000801.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.